Regeneron Pharmaceuticals, Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends

Biotech Giants' SG&A Expenses: A Decade of Divergence

__timestampAxsome Therapeutics, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20141392830504755000
Thursday, January 1, 20152419289838526000
Friday, January 1, 201663436481177697000
Sunday, January 1, 201772066911320433000
Monday, January 1, 201893515221556200000
Tuesday, January 1, 2019135980301834800000
Wednesday, January 1, 2020288967491346000000
Friday, January 1, 2021666462051824900000
Saturday, January 1, 20221592536612115900000
Sunday, January 1, 20233231230002631300000
Monday, January 1, 20244113590002954400000
Loading chart...

Unleashing the power of data

SG&A Expense Trends: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A expenses have consistently grown, peaking at approximately $2.63 billion in 2023, reflecting a strategic investment in operational expansion and market penetration. In contrast, Axsome Therapeutics, starting with a modest $1.4 million in 2014, has seen a staggering increase of over 23,000%, reaching $323 million in 2023. This dramatic rise underscores Axsome's aggressive growth strategy and its commitment to scaling operations. These trends highlight the dynamic nature of the biotech sector, where financial agility and strategic foresight are key to sustaining competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025